Elan

Elan Current Assets

The Current Assets of Elan (6099.T) as of Oct 9, 2026 is 18.47 B JPY. In the previous year, Current Assets was 16.87 B JPY — a change of 9.48% (higher).

Current Assets

18.47 BJPY

YoY

9.48%

Last updated:

Current Assets of Elan is 2025 18.47 B JPY. Current Assets of Elan was 2024 16.87 B JPY. It decreases by 9.48% higher compared to the previous year.

The Elan Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
6.99 B JPY
Jan 1, 2019
8.33 B JPY
Jan 1, 2020
10.18 B JPY
Jan 1, 2021
12.13 B JPY
Jan 1, 2022
14.08 B JPY
Jan 1, 2023
15.51 B JPY
Jan 1, 2024
16.87 B JPY
Jan 1, 2025
18.47 B JPY
The Elan Current Assets history
YEARCurrent AssetsYoY
18.47 BJPY+9.48%
16.87 BJPY+8.81%
15.51 BJPY+10.17%
14.08 BJPY+16.04%
12.13 BJPY+19.15%
10.18 BJPY+22.25%
8.33 BJPY+19.08%
6.99 BJPY+18.00%
5.93 BJPY+22.44%
4.84 BJPY+22.01%
3.97 BJPY+17.42%
3.38 BJPY+73.36%
1.95 BJPY+36.05%
1.43 BJPY—
Access this data via the Eulerpool API

Elan Stock analysis

What does Elan do? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elan stock

Current Assets of Elan is 18.47 B JPY in 2025.

Current Assets of Elan changed from 16.87 B JPY to 18.47 B JPY, representing a 9.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Elan since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Elan historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Elan

All Key Metrics — Elan